International Journal of Research Development and Technology

Vol 1, Issue 1, Year 2023 ISSN: 2584-0290

Web: www.ijrdt.com

Navigating the Complexities of Alopecia Areata: A Comprehensive Analysis

Anshu*[1], farooqui Nasir Ahmad [2], Bhardwaj Muskan [3], Jahan Iram [4], Ali Shadab [5], Ali Sayad Ahad[6].

IIMT college of Medical Science, Meerut, India, Anshu.gujjar360@gmail.com

Translam group of Institution, Meerut, India, nasirahmad21@gmail.com

IIMT college of Medical Science, Meerut, India, muskan198bhardwaj@gmail.com

IIMT college of Medical Science, Meerut, India, iramjahan1@gmail.com

IIMT college of Medical Science, Meerut, India, shadabali_pharma@gmail.com

IIMT college of Medical Science, Meerut, India, ahad_pharma@gmail.com

****

ABSTRACT

One prevalent type of body and head hair loss that doesn't leave scars is called alopecia areata (AA). In this Review, we studied the Pathogenesis of Alopecia Areata, Epidemiology, Cells implicated in alopecia areata immune reactions, Immunology, Environmental Factors, Genetic Factors, Causes of alopecia areata, Traditional Treatments of alopecia areata. The peer-reviewed literature release from 2010 & 2022 was thoroughly searched using Medline, Embase, Amed, Co-chrane Central Register of Controlled Trials, Psych INFO & Lilacs. All randomized controlled studies (RCTs) thatassessed efficacy systemic therapies for people with alopecia areata, totalis & universalis wereincluded.

Keywords: *Alopecia Areata, Alopecia Universalis, Pathogenesis, Epidemiology, hair Cycle, Hair follicle.*

****

Introduction:

Nonscarring alopecia areata (AA) is a type of balding confusion with eccentric course & a broad variety of signs. It affects both genders equally combined 2% life-time prevalence & no glaring race disparities pre-dominance [1, 2].

The disease is known significantly impact life's well- being-related components. The antigen stage is a moment of dynamic hair development. The antigen length doesn't decide length of hair will be. The basis of hair keratinizes just before tearing outermost limit, where hair is referred club hair. The follicular

connective tissue sheath swelling is and causes the strand to fold across the following catagen stage [3, 4].

No drugs for alopecia areata have yet to receive appro-val from US FDA. On the other hand, a few Alopecia Areata therapy options have been proposed, with varying degrees of success. The treatment of mature skin and basic immunomodulators are the best options, these therapy modalities are not yet backed by high-quality randomized controlled trials (RCTs). For a successful objective situated therapy with fewer side effects, detailed knowledge of the pathophysiological events is required [5].

We seek to comprehend the exact components associated with the pathophysiology of Alopecia Areata [6].

Since experts have been unable to pinpoint the cause of alopecia areata for a considerable amount of time, numerous associations have been put forthby trichology specialists. by the most strongly embedded irritation is affiliated ion. The association of alopecia areata with other immune system issues, such as morphed, atopic dermatitis, Hashimoto's thyroiditis, malignant pallor, and diabetes mellitus [7] as well as vitiligo, lichen planus, supports this theory. According to a review, patients with alopecia areata suffer from large sadness at a 39% lifetime prevalence rate [8].

Another review cross-sectional analysis examined the commonness among individuals with areata alopecia in secondary care consideration clinics. The study was following patients alopecia for than 11 years and found a high pervasiveness of distress and tension (25, 5%). A 9recent study recognized differential quality articulation designs in complete hair loss, as well as sketchy aggregates, proving that immuniogenisis of this clinical variation has exceptional perspectives loaning to these unmistakable examples of hair loss [10].

Currently, accessible proof proposes that alopecia areata can be viewed as a White blood cell-intervened immune system dis-ease in which slow loss security given by safe Honour of typical hair follicle plays a significant role.

Prognostic elements for Alopecia Areata incorporate the beginning stage, broad contribution (particularly Alopecia Totalis & Alopecia Universalis), and fast illness movement [11-12].

Other clinical structures incorporate inconsistent Alopecia, diffuse Areata, Areata reticular, Alopecia Areata sedatives, Alopecia Areata sisaipho, & peri nevoid Alopecia Areata. A new report recognized differential quality articulation designs in alopecia totalis & sketchy aggregates, showing that immune-pathogenesis of these clinical variations has remarkable perspectives loaning to these

unmistakable examples of balding. Clinically it has been seen in certainexaminations that it is now & again described by asymptomatic knobs, found generally on vertex & upper piece of occipital region [13].

A few patients lose hair in just a little fix, while others have greater & less regular inputs that are dispersed [14].

Disease progression can also be aided by psych neuroendocrine path-ways & environ-mental elements like viral content- nations, psycho-social stress, socio-economic difficulties & urban living [15].

Treatment objectives that incorporate ending infection movement and accomplishing agreeable hair regrowth. Nonetheless, the current management of alopecia totalis, alopecia areata, and single-stanza is poor with vulnerabilities encompassing treatment decision, length, sign and adequacy. Beginning treatment frequently includes the utilization of skin and intraregional corticosteroids. In broad and obstinate cases, fundamental specialists are tested, with decisions generally subject to clinician experience. In an agreement between patients, careers, family members and well-being ex-parts, evaluating viability of foundational treatments, Combined with immuno-suppressants, naturally, addressed 2 of main 3-examination vulnerabilities to be prioritized [16].

Hair loss in patches, typically on head, is primary adverse impact of alopecia Areata. However, alopecia areata can affect the eyelashes, eyebrows, & parts of body. Current understanding of Alopecia Areata pathogenesis ensnares a disintegration of insusceptible Honour of hair follicle, with entry of (Clusters of differentiation) CD4/CD8. Lymphocytes & an immune system tool that uses autoantigens that are melanogenesis-related proteins [17].

Micronutrients include minerals & trace elements, which are essential components of our diet but are only needed in minute amounts. These nutrients have a variety of physiological functions, including capacity to serve as organic substrates, chemicals & cofactors for proteins [18].

There are many reasons to consider role of vitamins in alopecia areata. Given their role in cell turnover, which occurs continuously in rapi-dly dividing hair folli-cle, vitamins are essential to normal hair follicle cycle [19].

Types of Alopecia Areata:

There are three kinds of alopecia.

Patchy Alopecia Areata: This condition results in a coin-sized or more patches, typically whether they are round & oval, on head & other areas of body where hair grows.



Fig.1: Patchy Alopecia Areata

Alopecia Totalis: The head of the person becomes completely hairless.



Fig.2: Alopecia Totalis



Fig.3: Alopecia

Alopecia Universalis: The person completely sheds their hair, leaving their entire body hairless.It's interesting.

Universalis Alopecia types are most normal in men:

1) Alopecia Areata:

Alopecia Areata: It is a condition where spots of baldness are caused by hair loss, but there are no scars in the afflicted areas.

Androgenic Alopecia:

Androgenetic alopecia in men (MAA), (male example sparseness) is the most prevalent source of male pattern baldness. Even though MAA is linked to a slightly increased risk of melanoma & non-melanoma cutaneous malignant growth of head, misery of MAA is primarily psychological. Although MAA affects person who is affected, premature MAA will inevitably have serious consequences. Myocardial localized necrosis, hypertension, and hypercholesterolemia are all allegedly associated with MAA. Skin finasteride and minoxidil (5 alpha re-reductase type II inhibitor) is primary FDA-USA-supported medications of MAA. The two experts illustrate the movement of partial hair re-growth & catch progression of going hairless. Dutasteride has been more effective & persuasive than finasteride.

2. Alopecia Barbae:

Alopecia Barbie is a particular type of balding that influences facial hair. Normally, a bare spot in your facial hair comes on

unexpectedly. It shows up as little roundabout bare patches.

Alopecia types are most common in women:

Alopecia Areata: It is a condition where spots of baldness are caused by hair loss, but there are no scars in the afflicted areas.

Androgenic alopecia: The most prevalent form of men's increasing hair loss condition is androgentic alopecia, also referred to male pattern baldness.

Postpartum Alopecia:

About 30–40% of hairs are retained in telogen period in cases of post-pregnancy alopecia [7].

It's been a while since I've been here, but I'm back. The gathered telogen stage hairs eventually undergo a widespread & rapid balding process. Though it is illogically discretionary to acquisition of mito-sis in hair follicle dur-ing preg-nancy, reasons for high % of hair follicles gathered in telogen stage are unclear. Even though cause of postpartum baldness is unknown, it is most likely related to female sex hormones because using or stop-ping using oral contraceptives can also cause telogen effluvium [20-21].

Three to 5-years may pass b/w hair loss cycles in post-pregnancy alopecia. Balding is always widespread but never finished. After an additional six to nine months, in individuals with no dietary deficiencies or other problems, hair will usually re-grow to normal amounts. However, some patients may grow more slowly, & their hair may be thinner than it was before delivery in some cases. There is little knowledge of how nursing, lack of nutrient admission before delivery, & post-partum worry link to post-pregnancy alopecia. It is unknown how much anxiety post-pregnancy baldness will create in patient.

Traction alopecia: People with hairstyles that continuously tug on the hair follicles are said to have "traction alopecia," which affects the hair. Afro-descendent women with spiral-curled, tightly curly hair are more likely to experience it. With the right instruction, traction alopecia may be a thing of the past [22].

Alopecia types most common in children

Alopecia areata, which often begins in adolescence.

Lichen Planopilaris:

An inflamed primary cicatricle alopecia called lichen planopilaris causes a variety of hair loss patterns. Lichen planopilaris' aetiology is unknown, but it is likely connected to that of lichenplanus [23] despite not being known.

Ophiasis Alopecia: Ophiasis is a form of Alo-pecia areata characteri-zed by symmetrical, band- like patterns of hair loss on scalp's occipital, temporal & parietal areas [24].

PathogenesisPathology:

Four stages have been noted in the histopathology of Alopecia Areata;

- Acute baldness
- Enduring baldness
- Partial change of telogen to anagen
- Recovery

Since the aetiology of alopecia areata was first described by Sauvages in 1760, several hypotheses have been established. Before neuropathic and hormonal disruption hypotheses were introduced, thepresence of an infectious or toxic substance was thought to be the primary cause12. The autoimmunity theory did, at last, become well-liked in the 1960s [25-26].

The frequent in:

Involvement of other immune-mediated illnesses like thyroiditis and vitiligo, as well as the re-response to immune-modifying therapies, provide evidence that alopecia areata may be auto-community. It is characterized by pathogenic disruption of hair development kinetics. The first occurrence of alopecia areata may be a fast transition of HFs from the antigen period through the catagen and telogen stages, resulting in the loss of a significant amount of hair.

Epidemiology:

Epidemiologic information on Alo-pecia Areata, which is better understand the behaviour and progress of the illness, is rare and frequently contradictory worldwide. Where there are fewer studies to draw from for the statistics, this problem is more noticeable [27, 28].

Between 0% and 8.6%alopecia areata sufferers describe a family's genealogy condition. Between 10% and 51.6% of infants have a family history of alopecia areata, according to reports? According to one research, men are more prone than women to have a family history.

Breakdown of the hair cycle:

The pilo-sebaceous component is made up of hair follicle near pili muscles, arteries, and the sebaceous duct. Its bottom portion is supplemented by cutaneous papilla. The term “in-infundibulum region of adult hair shaft that extends from the sebaceous gland's entrance through projection into skin. The protrusion, which is located in the dermis and is crucial to hair cycle because it houses the stem cells that will produce transit-amplifying cells during development phase, is next major structure. The bulb is situated (in a location for renewal) deeper than bulge. The cutaneous papilla is surrounded by bulb, which is made up of hair follicle tissue. The hair shaft structure contains. Melanocytes, which create colour of hair, are found in hair shaft matrix. The epithelium of hair shaft, which is made up of concentric layers creating the outermost exterior root sheath, interior of innermost hair

strand, root covering, is situated in supra bulbar region. (innermost hair filament, covering of base [27].

Growthin hair follicles happens in stages. An extended growth period (antigen), a brief short resting period,followed by a catagen transition phase. Make up each cycle. (Telogen). The cycle is restarted when resting period is over because hair falls out (exo-gen) & new hair begins to develop in follicle. The length of 3-stages varies significantly, & anagen's duration determines style. Especially its duration, being created. Each day, about 100 hair strands typically exit dormant period & fall out. Primary care providers are frequently general practitioners, but they are frequently uninformed about condition & may fail to send patients to dermatologist & administer proper treatment.

Fig:4 Immune reactions

Immune reactions and cells implicated in alopecia areata:

Immune system activity has a major effect on the growth and spread of alopecia areata. An antigen (hair development) phase lymphocytic infiltrate is visible in & around bottom portion of hair follicle in skin biopsies of afflicted individuals [26].

Hair loss & hair cycle dis- disturbance have both been related to autoimmune action near where hair shaft is located [29-31].

The mechanisms that initiate autoimmunity can be shared by alopecia areata and other autoimmune illnesses like thyroid condition, celiac condition, rheumatoid arthritis, & lupus erythematosus, which frequently coexist with it. Lymph node & spleen cells from mice with alopecia areata were injected into littermates with normal hair, findings of microarray study were confirmed. baldness in patches with help of cognate costimulatory lig-ands B7.1 & B7.2, which are found on surface of cells that exhibit antigens, onset in skin-grafted rodents could be suppressed. Alopecia areata-affected rodents were also able to regenerate hair after monoclonal anti-bodies were used to eliminate CD4+ & CD8+ expressing cells from their bodies.

A) As the primary cause of illness, CD8+ cells:

CD8(Cluster of differentiation 8)+NKG2D (Natural Killer 2D)+T cells (cytotoxic T-cells) Significanthair loss in alopecia areata has been linked to CD 8 + N K G 2 D +T cells (cyto-toxic T-cells), which are the first to enter region surrounding hair follicles. Skin samples from random cases and suitable controls were takenat 5, 10 & 20 weeks after skin transplant development of alopecia areata (for more information, see the online Additional Information for Materials & Methods). In line with earlier discoveries in rodent and human alopecia areata, messenger RNA was elevated by 10 weeks. There is proof that Granzyme B (GZMB) is a lethal substance made by effector CD8+ T cells, & is used by CD8+T cells as a weapon against hair follicle. In hair shafts of alopecia areata patients [25]. However, only GZMB transcripts are up regulated in alopecia-affected C3H/HeJ animals, while Tia1 expression is not, indicating GZMB production might be more impor-tant for CD8+ T cell -driven disease [32].

B) Treg & Th17 cells' roles in alopecia areata:

Recent research has suggested that (T-helper) cells may also contribute to aetio-logy of illness [33].

Pro-inflammatory mediators secreted by (T-helper) Th-17 cells, which secrete (Inter-leukin) IL-17, IL-22 & IL-23, are crucial in emergence of inflammatory & autoimmune illnesses like alopecia areata [34-35].

C) A connection between innate & adaptive reactions via plasmacytoid dendritic cells:

1. **Alopecia areata cytokine action.**

   IFN-γ :(Interferon-gamma): In addition to other effects, IFN-γ also prevents dermal papilla cells from maintaining anagen's hair development, as demonstrated in human research [36].

   When compared to controls, individuals with alopecia total is & universalis had much higher blood levels of IFN-, but there hasn't been any obvious difference b/w patients with localised alopecia areata & those with more severe types. Furthermore, human alopecia areata studies by Deaths et al. show that antigen-specific T lymphocytes from patients with severe form of disease appear to have some sort of intrinsic defect. The creation of IFN- was not entirely hostile to it, which might be an indication of partial tolerance in epi-dermis of these patients. Despite aforementioned, elevated serum IFN-levels in people with alopecia areata may indicate presence of inflammation, especially in the extensive forms of disease. Serum IFN-level measurements may also be

used as a prognostic tool or to distinguish between people who are likely to develop alopecia universalis & those who only have a local disease. Future research might be able to assess changes in IFN-γ levels in in-individuals who have spontaneousontaneous regression or progressive disease expansion [37].

2. **Interleukins:**

Studies have demonstrated that interleukins-1 significantly inhibits human hair development in vitro and is a highly effective inducer of hair loss. They have shown that during triggered murine hair cycle, interleukins-1 significantly increase start of sponta-neous catagen phase, peaking during telo-gen phase & being linked to higher expression of signal-trans-ducing type-I interleukins-1 receptor. Alopecia areata-like spotty hair loss is also ob- served in transgenic rodents overexpressing interleukins-1a in skin, according to research by Groves et al. [38].

While polymorphisms decide the disease's vulnerability and intensity, excessive production is seen in alopecia areata-affected human scalp regions, especially in the early phases of condition. In presence of interleukins-1a and the interleukins-1 receptor block- er. Clinically speaking, patients with low levels of interleukins-1 receptor antagonist the inter- leukins-1 natural antagonist due to gene polymorphisms experience a more severe disease [39], whereas those with severe alopecia areata hair loss have a higher frequency of interleukins-1 receptor anta-gonistgene allele2 [40].

Last but not least, in line with foregoing, it has been demonstrated steady-state levels of interleukins-10-mRNA rise following an effective DCP therapy, making interleukins-10 a crucial inhibitor Th1 cyto-kine production. [41].

3. **TNF-*α:* Alpha-Tumor Necrosis Factor**

The aetiology of alopecia areata is well known to be significantly influenced by TNF-α. TNF-α, one of many cytokines produced by epidermis keratinocytes, is wellrecognized for being a very effective proliferative inhibitor. In vitro studies have shown TNF-, IL1-, & IL1-induced matrix cell vacillation within folli-cle bulb & a decrease in matrix's size, as well as dis-organisation of folli-cular melano- cytes, abnormal differen-tiation & kera- tinization of para-cortical cells, & kera- tinization of inner root sheath, all occur. Adreno-cortico-tropic hormone levels in blood

& cutaneous ACTH receptor expre-ssion

levels interact favourably under chronic stress in humans, presumably pointing to a patho-physiologic process underlying well-known role of stressors in alopecia areata. The serum of alopecia patients, & in parti-cular subset with numerous lesions, has been found to contain extremely high levels of BAFF a member of TNF family pro-duced by myeloid lineage cells. As pre-viously mentioned, it is believed that IFN-, which is widely known to be raised in individuals with alopecia, facilitates production of BAFF. Studies on mice suggest that BAFF may potentially activate T-cells & so promote Th1 response, which would lead to pro-duction of IFN- & per-sistence of illness [42].

Immunology of Alopecia Areata:

Normal hair growth:

Hair cells go through continuous, cyclical change. Three stages of hair development have historically been recognized: antigen (a time of extremely fast growth, pigmentation, and production of hair shafts), catagen (a phase of regression), & telogen (a phase of rest) [43]. During catagen, bottom "bulb" region of the hair shaft undergoes remodeling. The isthmus and infundibulum, which are divided by the sebaceous gland channel, are located in top, non-cycling region of hair follicle. The APM enters at lowest part of isthmus, where hair bulge rests on outer root sheath. Between isthmus & outside world, inner root sheath acts as a mechanical buffer. It also creates a safe habitat for bulge. Keratinocytes, melanocytes, arrestor pili myocytes, & progenitor cells from hair follicles can all be found in the protrusion. When lymph node & spleen cells from mice with alopecia areata were transplanted into littermates with normal hair, alopecia areata trait was transmitted, providing further support for findings of microarray study. By modulating B7.1- B7.2-specific polyclonal anti-bodies, alopecia areata development in skin-grafted rodents could be prevented. Additionally, hair could regenerate in animals with chronic alopecia areata when CD4+ and CD8+ expressing cells were eliminated using monoclonal antibodies.

Genetic factor

In aetiology of alopecia areata, genetics is crucial. For instance, the onset of the illness and the patterns of hair loss were comparable in monozygotic siblings with Alopecia Areata follow- ing mumps infection [44].

Particular genes including according to reports, the genes DQB1*03 and DRB1*1104 are indicators of AA vulnerability. [45].

AT/AU may be linked to the HLA genes DQB1*0301 and HLA-DR11 and HLA-DQ7) DRB1*1104,respectively) [46].

Candidate gene association studies were the initial genetic re- search done in AA. Before the availability of genome-wide research, early candidate gene association studies

demonstrated a link b/w AA & a significant many immune-related genes, such as HLA-DQB1, HLA-DRB1, NOTCH4, and MICA, among others [47].

Linkage or association was found on numerous chromosomes in GWAS (genome-wide association study) evaluations, as well as family-based linkage research, which was made possible in large part by National Alopecia Areata Registry collection [48]. This indicates that alopecia areata is a highly complicated polygenic condition. These findings supported previous quantitative trait locus analysis studies using an alopecia area-ta rodent model, which frequently yielded comparable, if not identical, results [49-50].

Causes of alopecia areata:

The Alopecia area precise reason is still unknown. The majority of the research suggests an au- autoimmune genesis, a genetic predisposition, and outside influences. Alopecia areata patients' immune systems are thought to erroneously target their hair follicles, which impairs their capacity tocreate new hair. According to studies, 10–25% of individuals with alopecia had a family member who also suffered from the condition.

Traditional Treatments of alopecia areata:

Corticosteroids:

Steroids Intralesional: Mild Cases one of the first options for treating AA in adults has-torically been Intralesional steroids, typically tri-amcinolone acetonide (2.5-10 mg/ml). Treatment is given every 4-6 weeks on average [51].

Patients with less severe diseases should not use this therapy because it is best adapted to patients with restricted hair loss. Skin loss, a chance of cataracts, and elevated intraocular pressure are major adverse effects when addressing the eyebrows [52].

Topical Steroids: mild Cases: Use of Topical Steroids in Mild Cases Topical corticosteroids are a popular therapy for many inflammatory skin conditions and are still used as 1st line of defence in both children & adults, particularly in case of patchier, mild cases of AA [53]. 0.05% clobetasol propionate, at a limit of 2.5g daily, is the most frequently recommend- ed form; other lotions, creams, ointments, foams, or sprays are also acceptable.

Aside from head folliculitis, relapse rates have been reported to range from 37 to 63% [54].

Systemic Steroids:

Moderate to Severe Cases: In one research, a dietary dose of 300 milligrams of prednisone given once per month resulted in a full recovery in 41% of patients [55]. A study using a dummy study of 200 mg/weekly of oral prednisone in therapy of severe alopecia areata found a comparable outcome. 25% of patients experienced relapses, and 55%

reported experiencing adverse treatment effects. In acomparison study, individuals with 40 milligrams of triamcinolone acetonide intramuscularly once per month used to treat had a higher reaction rate than those who receive 0.5mg/day of oral dexamethasone treatment. Patients who received oral prednisone in the same study experienced heartbeat treatment of 80-mg for 3 straight days once every three months and had a 7% impairment of adrenocortical reserve compared to 23% of those treated with intramuscular triamcinolone acetonide. In a 139-subject study receiving pulse corticosteroid treatment, 59.4% of those with a new start illness (alopecia areata duration up to 6 months) experienced a favorable reaction, as opposed.

Topical Immunotherapy:

Topical sensitizers like Squaric acid, diphenylcyclopropenone dibutyl ester (SADBE), and dinitrochlorobenzene have been used to cure alopecia areata. Dinitrochlorobenzene is no longer used because the Ames test revealed it to be carcinogenic. Due to its sensitivity to light, diphenylcyclopropenone should be shielded from sunlight. Topical sensitizers' mode of action may involve antigenic competition, peribulbar CD4/CD8 lymphocytes ratio shifts, and perifollicular lymphocyte death.

Diphenylcyclopropenone: The preferred dermal sensitizer is diphenylcyclopropenone.

Squaric Acid Dibutylester: SADBE costs a lot of money and is unstable in acetone.

Anthralin: Topical Tacrolimus Anthralin must be administered in a sufficient quantity (0.5%–10%) and regularly enough (daily) to cause a moderate irritant response. One of the potential side effects of anthralin is severe itchiness and discolouration of the skin and clothing.

Topical Minoxidil: The majority of research on alopecia universalis and alopecia totalis has found no benefit from oral minoxidil. Adjuvant treatment frequently involves the use of Minoxidilfoam or fluid, 5% in conjunction with additional medicinal drugs. Contact rash and face hy- hypertrichosis are among topical minoxidil unfavorable effects [56].

Topical Bimatoprost: By chance, hypotrichosis of the eyebrows was treated with this method. There have been numerous accounts about prostaglandin analogues as a therapy for eyelashes in alopecia areata since Johnstone first described in 1997, oral latanoprost was used to treat the first instance of eyelash hypertrichosis. It is the same as the ophthalmic solution for treating glaucoma (Lumigan) [57].

Cyclosporine, Methotrexate, Sulphasalazine, and Azathioprine:

Cyclosporine: Oral cyclosporine has a 25%–76.6% effectiveness rate. According to a recent re- search. A favorable reaction to oral cyclosporine can be expected if the serum levels of soluble interleukins-2 receptors and interleukins-18 are high and low, respectively. Due to its adverse event characteristics (nephro-toxicity, immune supper-ssion, & hyper-tension) & high recurrence rate (up to 100%), oral cyclosporine is usually not recommended for use in individuals with alopecia areata [58].

Methotrexate: In a long-term follow-up, 33 patients with alopecia areata who received prednisone 10-20mg/day alone or in combination with metho-trexate saw total hair regrowth in 57 & 63% of patients, respectively [59].

Sulphasalazine: Bowel inflammation, inflammatory arthritis, and other inflammatory and autoimmune illnesses have all been successfully treated over an extended period with sulfasalazine. In several case studies and case series, sulfasalazine treatment for alopecia areata resulted in ex- cellent hair growth. Using enteric-coated pills, ingesting the medicine with food, & beginning with smaller dosages, gastrointestinal problems can be reduced. Patients should initially undergo a full blood count, liver function tests, creatinine testing, and a determination of their glucose-6-phosphate dehydrogenase levels. During the first three months of treatment, full blood counts and assays for liver function ought to be done at 2-4 week intervals. The recurrence rates range from 22.7% to 45.5%.

Azathioprine: A wide variety of autoimmune illnesses have been treated with the immunosuppressive medication azathioprine, a thiopurine derivative. It prevents DNA synthesis, lowering cell growth overall, particularly in T & B lympho-cytes. Other antigen-presenting cells in epi-dermis, such as Langer-hans cells, are also decreased by azathioprine. In a recent pilot trial, 20 patients were given azathioprine as monotherapy at a dose of 2 mg/kg/day & mean rate of hair development was 52.3% and 38.4%.

Tumor Necrosis Factor Inhibitors:

With an estimated lifetime chance of 2%, A type of non-scarring alopecia areata autoimmune alopecia. Interleukins-1 & TNF are examples of pro-inflammatory cytokines.-appear to play a significant part in development of the illness, even though the pathogenesis is not completely understood. Tumour Necrosis Factor inhibitors should therefore be a successful therapy, one would think. Alternatives for this circumstance. Studies have not only refuted this but it has also been discovered that alopecia areata can develop while taking TNF inhibitors. Since the 1st case, which involved the use of the TNF inhibitor infliximab, was described in 2004, we have found 34 instances in the literature. It

might only impact the edges of the hair (Ophiasis). Clinically, it has been noted in a few studies that Alopecia Areata can occasionally be distinguished by benign nodules, which are primarily found on the head and the top portion of the occipital region.

Conclusion: The use of a special community-based data resource, the sheer volume of cases, and the high de- greeof diagnostic precision are the study's assets when it comes to the prevalence of Alopecia Arecta. Thefact that the data were acquired retroactively from medical documents is a weakness. The severity of Alopecia Arecta, later courses, and family background were among the topics about which information was not always readily accessible. With a lifelong chance of about 2% in world's population, Alopecia Arecta is most common autoimmune disease & 2nd most common cause of hair loss after androgenetic alopecia. Psychiatric and medical co-morbidities like melancholy, anxiety, several autoimmune diseases, and a higher worldwide dis- ease load are all linked to Alopecia Arecta. In individuals with Alopecia Arecta and variants, we particularly looked at HRQoL. Patients with Alopecia Arecta routinely exhibit lower HRQoL than control patients, with vitality, mental health, mood, and social performance being the most adversely impacted. Future research should focus on conducting higher-quality RCTs with ex-explicitly specified endpoints to further define the effectiveness of systemic therapies in alopecia areata. There is not enough high-quality data to determine whether some frequently used therapy choices, such as oral and topical anti- hormonal medications, are effective.

References:

1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton III LJ. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. InMayo Clinic Proceedings 1995 Jul 1 (Vol. 70, No. 7, pp. 628-633). Elsevier.
2. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review Clinical, cosmetic and investigational dermatology. 2015 Jul 24:397-403.
3. Shi Q, Duvic M, Osei JS, Hordinsky MK, Norris DA, Price VH, Amos CI, Christiano AM, Mendoza TR. Health-related quality of life (HRQoL) in alopecia areata patients a secondary analysis of the National Alopecia Areata Registry Data. InJournal of Investigative DermatologySymposium Proceedings 2013 Dec 1 (Vol. 16, No. 1, pp. S49-S50). Elsevier.

4. Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. Journal of the American Academy of Dermatology. 2016Oct 1;75(4):806-12.
5. Lai VWY, Chen G, Gin D, et al. Systemic treatments for alopecia areata: A systematic review Australas J Dermatol. 2019;60:e1–e13.
6. Kavak A, Baykal C, Özarmağ an G, Akar U. HLA in alopecia areata. International journal of dermatology. 2000 Aug;39(8):589-92.
7. Amin SS, Sachdeva S. Alopecia areata: A review. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2013 Jul 1;17(2):37-45.
8. Brenner W, Diem E, Gschnait F. Coincidence of vitiligo, alopecia areata, onychodystrophy, localised scleroderma and lichen planus. Dermatology. 1979;159(4):356-60.
9. Colón EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK. Lifetime prevalence of psy- chiatric disorders in patients with alopecia areata. Comprehensive psychiatry. 1991 May 1;32(3):245-51.
10. Alfani S, Antinone V, Mozzetta A, Di Pietro C, Mazzanti C, Stella P, Raskovich D, Abeni D. Psychological status of patients with alopecia areata. Acta dermato-venereologica. 2012 May 1;92(3).
11. Vestey JP, Savin JA. Natural history of severe alopecia areata. British Journal of Dermatol- ogy. 1987 Oct;117(4):531.
12. Gilhar A, Etzioni A, Paus R. Alopecia areata. New England Journal of Medicine. 2012 Apr 19;366(16):1515-25.
13. Tsuruta D, Hayashi A, Kobayashi H, Nakogowa K, Furukawa M, Ishii M. Psuedocyst of the scalp. Dermatology 2005; 210:333-335
14. Finner AM (2011) Alopecia areata: clinical presentation, diagnosis, and unusual cases. Der- matol Ther 24(3):348–354
15. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628–33.
16. Macbeth AE, Tomlinson J, Messenger AG et al. Establishing and prioritising research questions for the treatment of alopecia areata: the Alopecia Areata Priority Setting Partnership. Br. J. Dermatol. 2017; 176: 1316–20.
17. Islam N, Leung PSC, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive

review. Autoimmun Rev. 2015;14:81–9.

18. Mason JB. 218 vitamins, trace minerals, and other micronutrients, twenty-fifth edition Goldman-Cecil Med. 2016;2:1445.e1–1455.e1.
19. Handjiski BK, Eichmu¨ller S, Hofmann U, et al. Alkaline phosphatase activity and localiza- tion during the murine hair cycle. Br J Dermatol. 1994;131:303–10.
20. Baker H. Adverse cutaneous reaction to oral contraceptives. Br J Dermatol 1969;81:946-9. 21. Kligman AM. Pathologic dynamics of reversible hair loss in humans. Telogen effluvium. Arch Dermatol 1961;83:175-98.
21. Goren A, Wei L, Tan Y, Kovacevic M, McCoy J, Lotti T. Frontal pattern hair loss among Chinese women is frequently associated with a ponytail hairstyle. Dermatol Ther. 2019 Jan;32(1):e12784.
22. Ocampo-Garza J, Tosti A. Trichoscopy of Dark Scalp. Skin Appendage Disord. 2018 Nov;5(1):1-8.
23. Choi JW, Loh SH, Lew BL, Sim WY. Histopathologic features of opiates-type alopecia area- ta. In journal of the American academy of dermatology 2017 Jun 1 (Vol. 76, No. 6, pp. AB156-AB156). 360 Park avenue south, New York, Ny10010-1710 USA: MOSBY-ELSEVIER.
24. Dai Z, Xing L, Cerise J, Wang EH, Jabbari A, de Jong A, Petukhova L, Christiano AM, Clynes R. CXCR3 blockade inhibits T cell migration into the skin and prevents the development of alopecia areata. The Journal of Immunology. 2016 Aug 15;197(4):1089-99.
25. Ourhroui A, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a once- monthly oral pulse. InAnnales de Dermatologie et de Venereologie 2010 Aug 17 (Vol. 137, No. 8-9,pp. 514-518).
26. Volpe E, Pattarini L, Martinez-Cingolani C, Meller S, Donnadieu MH, Bogiatzi SI, Fernan- dez MI, Touzot M, Bichet JC, Reyal F, Paronetto MP. Thymic stromal lymphopoietin links ker- atinocytes and dendritic cell–derived IL-23 in patients with psoriasis. Journal of Allergy and Clinical Immunology. 2014 Aug 1;134(2):373-81.
27. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. The lifetime incidence risk of Alope- cia Areata was estimated at 2.1 per cent by Rochester Epidemiology Project, 1990–2009. J

Invest Dermatol. 2014 Apr;134 (4):1141-2.

28. Van Scott EJ. Morphologic changes in pilosebaceous units and anagen hairs in alopecia area- ta. Journal of Investigative Dermatology. 1958 Jul 1;31(1):35-43.
29. McElwee KJ, Tobin DJ, Bystryn JC, King Jr LE, Sundberg JP. Alopecia areata: an autoim- mune disease? Experimental dermatology. 1999 Oct;8(5):371-9.
30. McPhee CG, Duncan FJ, Silva KA, King Jr LE, HogenEsch H, Roopenian DC, Everts HB, Sundberg JP. Increased expression of Cxcr3 and its ligands, Cxcl9, and Cxcl10, during the de- velopment of alopecia areata in the mouse. The Journal of investigative dermatology. 2012 Jun;132(6):1736.
31. Malik K., Guttman-Yassky E. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons fromAtopic Dermatitis and Other Inflammatory Skin Diseases. *J. Investig. Dermatol. Symp. Proc.* 2018;19:S62–S64. doi: 10.1016/j.jisp.2017.10.005.
32. Giordano C.N., Sinha A.A. Cytokine pathways and interactions in alopecia areata. Eur. J. Dermatol. 2013;23:308–318.
33. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmunity reviews. 2014 Jun 1;13(6):668-77.
34. M. Sato-Kawamura, S. Aiba, and H. Tagami, “Strong expression of CD40, CD54 and HLA- DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopatho- logical features in alopecia areata,” Archives of Dermatological Research, vol. 294, no. 12, pp. 536–543, 2003.
35. E. Arca, U. Mus bak, A. Akar, A. H. Erbil, and H. B. Tas tan, “Interferon-gamma in alopecia areata,” European Journal of Dermatology, vol. 14, no. 1, pp. 33–36, 2004.
36. R. Hoffmann, E. Wenzel, A. Huth, et al., “Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone,” Journal of Investigative Dermatology, vol. 103, no. 4, pp. 530–533, 1994.
37. R. W. Groves, I. R. Williams, S. Sarkar, K. Nakamura, and T. S. Kupper, “Analysis of epi- dermal IL-1 family members in vivo using transgenic mouse models,” Journal of Investigative Dermatology, vol. 102, p. 556, 1994.
38. R. Hoffmann, “The potential role of cytokines and T cells in alopecia

areata, Journal of In- vestigative Dermatology Symposium Proceedings, vol. 4, no. 3, pp. 235–238, 1999.

39. J. K. Tarlow, F. E. Clay, M. J. Cork, et al., “Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene,” Journal of Investigative Dermatol- ogy, vol. 103, no. 3, pp. 387–390, 1994.
40. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. InSeminars in immunology 2006 Oct 1 (Vol. 18, No. 5, pp. 284-289). Academic Press.
41. Paus R, Cotsarelis G (1999): The biology of hair follicles. N Engl J Med 341: 491-497.
42. Stankler L. Synchronous alopecia areata in two siblings: a possible viral aetiology. The Lancet. 1979 Jun 16;313(8129):1303-4.
43. Akar A, Arca E, Erbil H, Akay C, Sayal A, Gür AR. Antioxidant enzymes and lipid peroxida- tion in the scalp of patients with alopecia areata. Journal of dermatological science. 2002 Aug 1;29(2):85-90.
44. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associa- tionshelp to define two types of alopecia areata. Journal of the American Academy of Dermatol- ogy. 1995Nov 1;33(5 Pt 1):757-64.
45. Barahmani N, De Andrade M, Slusser JP, Wei Q, Hordinsky M, Price VH, Christiano A, Nor- ris D, Reveille J, Duvic M. Human leukocyte antigen class II alleles are associated with risk of alopecia areata. The Journal of Investigative Dermatology. 2007 Jul 19;128(1):240-3.
46. McPhee CG, Duncan FJ, Silva KA, King Jr LE, HogenEsch H, Roopenian DC, Everts HB, Sundberg JP. Increased expression of Cxcr3 and its ligands, Cxcl9, and Cxcl10, during the de- velopment of alopecia areata in the mouse. The Journal of investigative dermatology. 2012 Jun;132(6):1736.
47. Sundberg JP, Boggess D, Silva KA, McElwee KJ, King LE, Li R, Churchill G, Cox GA. The major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alope- ciaareata in C3H/HeJ mice. Journal of investigative dermatology. 2003 May 1;120(5):771-5.
48. Sundberg JP, Boggess D, Silva KA, McElwee KJ, King LE, Li R, Churchill G, Cox GA. The major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alope- ciaareata in C3H/HeJ mice. Journal of investigative dermatology. 2003 May 1;120(5):771-5.

49. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol JDD. 2009;8(10):909–12.
50. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic cor- ticosteroids. Curr Opin Ophthal- mol. 2000;11(6):478–83.
51. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05 % under occlusionin the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49(1):96–8.
52. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluoci- nolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including the histologic study of the ensuing localized acneform response. Dermatologica. 1970;141(3):193–202.
53. Ourhroui A, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a once- monthly oral pulse. InAnnales de Dermatologie et de Venereologie 2010 Aug 17 (Vol. 137, No. 8-9,pp. 514-518).
54. Philpott MP, Sanders DA, Bowen J, Kealey T. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for inter- leaking-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol. 1996 Dec;135(6):942-8. doi: 10.1046/j.1365-2133.1996.d01-1099.x. PMID: 8977716.
55. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. *Am J Ophthalmol.* 1997;124:544–7.
56. Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2 Pt 1):242–250.
57. Chartaux E, Joly P. Long-term follow-up of the efficacy of methotrexate alone or in combinationwith low doses of oral corticosteroids in the treatment of alopecia areata totalis or univer- salis. Ann Dermatol Venereol. 2010;137(8–9):507–513.